Researches and develops biopharmaceutical products. Manufactures plasma-derived therapies for immunodeficiency and bleeding disorders. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 11% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 11% a year on average.
The company sells $16.0B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $2.92 per share each year — regular cash for whoever holds the stock.
A loss of $2.6B against $16.0B in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Against everything we grade, CMXHF lands near the bottom. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CMXHF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
Not covered, because the filings we hold do not carry it: the revenue breakdown.